{"id":"placebo-matching-with-dapagliflozin","safety":{"commonSideEffects":[{"rate":"10–15","effect":"Genital mycotic infections"},{"rate":"5–10","effect":"Urinary tract infections"},{"rate":"5–10","effect":"Polyuria"},{"rate":"5–8","effect":"Hypotension"},{"rate":"0.1–0.5","effect":"Diabetic ketoacidosis"}]},"_chembl":{"chemblId":"CHEMBL429910","moleculeType":"Small molecule","molecularWeight":"408.88"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Dapagliflozin blocks SGLT2, a transporter protein in the proximal tubule of the kidney that normally reabsorbs filtered glucose back into the bloodstream. By inhibiting this transporter, the drug allows excess glucose to be excreted in the urine, thereby reducing blood glucose concentrations. This mechanism is independent of insulin secretion or action, making it effective across different diabetes phenotypes.","oneSentence":"Dapagliflozin inhibits sodium-glucose cotransporter 2 (SGLT2) in the kidney to increase urinary glucose excretion and lower blood glucose levels.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:27:58.994Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Type 2 diabetes mellitus"},{"name":"Heart failure with reduced ejection fraction"},{"name":"Chronic kidney disease"}]},"trialDetails":[{"nctId":"NCT06742723","phase":"PHASE3","title":"A Phase III Renal Outcomes and Cardiovascular Mortality Study to Investigate the Efficacy and Safety of Baxdrostat in Combination With Dapagliflozin in Participants With Chronic Kidney Disease and High Blood Pressure","status":"RECRUITING","sponsor":"AstraZeneca","startDate":"2025-03-03","conditions":"Chronic Kidney Disease and Hypertension","enrollment":5000},{"nctId":"NCT06307652","phase":"PHASE3","title":"Study to Evaluate the Effect of Balcinrenone/Dapagliflozin in Patients With Heart Failure and Impaired Kidney Function","status":"RECRUITING","sponsor":"AstraZeneca","startDate":"2024-04-12","conditions":"Heart Failure and Impaired Kidney Function","enrollment":4800},{"nctId":"NCT07222917","phase":"PHASE2","title":"A Phase IIb Study to Evaluate the Effect of Dapagliflozin in Combination With Baxdrostat Compared With Baxdrostat on Albuminuria in Participants With Chronic Kidney Disease and High Blood Pressure.","status":"RECRUITING","sponsor":"AstraZeneca","startDate":"2025-12-05","conditions":"Chronic Kidney Disease and Hypertension","enrollment":218},{"nctId":"NCT06677060","phase":"PHASE3","title":"Phase III Study Investigating Heart Failure and Cardiovascular Death With Baxdrostat in Combination With Dapagliflozin","status":"RECRUITING","sponsor":"AstraZeneca","startDate":"2025-03-14","conditions":"Heart Failure","enrollment":11300},{"nctId":"NCT07323524","phase":"PHASE4","title":"Dapagliflozin in Active Lupus Nephritis","status":"NOT_YET_RECRUITING","sponsor":"Brigham and Women's Hospital","startDate":"2026-02-01","conditions":"Lupus Nephritis (LN)","enrollment":33},{"nctId":"NCT06268873","phase":"PHASE3","title":"A Phase III Study to Investigate the Efficacy and Safety of Baxdrostat in Combination With Dapagliflozin on CKD Progression in Participants With CKD and High Blood Pressure.","status":"ACTIVE_NOT_RECRUITING","sponsor":"AstraZeneca","startDate":"2024-03-29","conditions":"Chronic Kidney Disease and Hypertension","enrollment":2554},{"nctId":"NCT06269484","phase":"PHASE2","title":"A Phase IIb Study to Evaluate the Safety of Zibotentan/Dapagliflozin in Participants With Cirrhosis-ZEAL-UNLOCK","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2024-02-15","conditions":"Liver Cirrhosis","enrollment":73},{"nctId":"NCT05374291","phase":"PHASE3","title":"The RENAL LIFECYCLE Trial: A RCT to Assess the Effect of Dapagliflozin on Renal and Cardiovascular Outcomes in Patients With Severe CKD","status":"ENROLLING_BY_INVITATION","sponsor":"University Medical Center Groningen","startDate":"2022-11-08","conditions":"Kidney Disease, Chronic, Renal Transplant Failure, Heart Failure","enrollment":1750},{"nctId":"NCT05468203","phase":"PHASE3","title":"PREVENTion With Sglt-2 Inhibition of Acute Kidney Injury in Intensive Care","status":"RECRUITING","sponsor":"The George Institute","startDate":"2023-11-29","conditions":"Acute Kidney Injury","enrollment":3000},{"nctId":"NCT06922656","phase":"PHASE4","title":"Can the Addition of Pioglitazone to SGLT2 Inhibitor in Type 1 Diabetic Patients Amplify the Decrease in HbA1c and Prevent the Increase in Plasma Ketone Concentration?","status":"NOT_YET_RECRUITING","sponsor":"Dasman Diabetes Institute","startDate":"2025-09-15","conditions":"Type 1 Diabetes","enrollment":60},{"nctId":"NCT05762952","phase":"PHASE1","title":"Effect of Dapagliflozin on Microvascular Function in Women With Symptoms of Coronary Artery Disease","status":"RECRUITING","sponsor":"University of Virginia","startDate":"2023-06-06","conditions":"Myocardial Ischemia","enrollment":40},{"nctId":"NCT05516498","phase":"PHASE2","title":"Zibotentan and Dapagliflozin Combination, EvAluated in Liver Cirrhosis (ZEAL Study)","status":"TERMINATED","sponsor":"AstraZeneca","startDate":"2022-10-31","conditions":"Liver Cirrhosis","enrollment":205},{"nctId":"NCT06054035","phase":"PHASE4","title":"SGLT2 Inhibition in Addition to Lifestyle Intervention and Risk for Complications in Subtypes of Patients With Prediabetes","status":"RECRUITING","sponsor":"University Hospital Tuebingen","startDate":"2023-10-26","conditions":"Type2diabetes, PreDiabetes, Renal Failure","enrollment":170},{"nctId":"NCT04591639","phase":"NA","title":"The DAPA-MEMRI Trial","status":"RECRUITING","sponsor":"University of Edinburgh","startDate":"2020-08-19","conditions":"Heart Failure, Diabetic Cardiomyopathies","enrollment":160},{"nctId":"NCT06350123","phase":"PHASE2","title":"Efficacy, Safety and Tolerability of Balcinrenone/Dapagliflozin Compared to Dapagliflozin in Adults With Chronic Kidney Disease","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2024-05-01","conditions":"Chronic Kidney Disease","enrollment":324},{"nctId":"NCT05884866","phase":"PHASE2","title":"A Study to Investigate the Mechanistic Effects of Dapagliflozin Alone or in Combination With Balcinrenone, Compared to Balcinrenone and Placebo on Body Fluid and Electrolyte Handling and Energy Metabolism in Participants Over 50 Years of Age With Chronic Kidney Disease.","status":"RECRUITING","sponsor":"Klinikum Nürnberg","startDate":"2023-07-13","conditions":"Chronic Renal Failure, Mechanistic Effects of SGLT2 Inhibition and/ or MR Antagonism on Body Fluid and Electrolyte Homeostatis, Chronic Kidney Disease Stage 3","enrollment":100},{"nctId":"NCT05570305","phase":"PHASE2","title":"Zibotentan and Dapagliflozin in Patients With Type 2 Diabetes and Elevated Albuminuria","status":"COMPLETED","sponsor":"University Medical Center Groningen","startDate":"2022-10-06","conditions":"Chronic Kidney Diseases","enrollment":42},{"nctId":"NCT05852704","phase":"PHASE3","title":"SGLT2 Inhibitor TrEatment iN Patients Awaiting cOronary arTery bYpass Surgery to Reduce Post-opErative AF","status":"RECRUITING","sponsor":"Region Örebro County","startDate":"2024-04-04","conditions":"Chronic Coronary Syndrome, Atrial Fibrillation","enrollment":800},{"nctId":"NCT04965935","phase":"PHASE3","title":"Efficacy, Mechanisms and Safety of SGLT2 Inhibitors in Kidney Transplant Recipients","status":"COMPLETED","sponsor":"University Health Network, Toronto","startDate":"2021-07-15","conditions":"Kidney Transplant Recipients, Post-transplant Diabetes Mellitus, Type 2 Diabetes","enrollment":52},{"nctId":"NCT04564742","phase":"PHASE3","title":"Dapagliflozin Effects on Cardiometabolic Outcomes in Patients With an Acute Heart Attack.","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2020-12-22","conditions":"Acute Myocardial Infarction, Heart Failure","enrollment":4017},{"nctId":"NCT06619600","phase":"PHASE3","title":"Effect of Dapagliflozin in Myocardial Fibrosis and Ventricular Function in Patients With a ST-segment Elevation Myocardial Infarction","status":"ACTIVE_NOT_RECRUITING","sponsor":"Hospital Clinic of Barcelona","startDate":"2021-05-30","conditions":"ST-segment Elevation Myocardial Infarction (STEMI), Diabetes Mellitus, Heart Failure","enrollment":54},{"nctId":"NCT04492722","phase":"PHASE2","title":"A Study to Evaluate the Safety and Efficacy of AZD5718 in Participants With Proteinuric Chronic Kidney Disease","status":"TERMINATED","sponsor":"AstraZeneca","startDate":"2020-10-01","conditions":"Chronic Kidney Disease","enrollment":613},{"nctId":"NCT04234867","phase":"PHASE1","title":"Study to Explore the Effect of Dapagliflozin and Stress in Adolescent and Adult Subjects With Type 1 Diabetes (T1D)","status":"TERMINATED","sponsor":"Kinderkrankenhaus auf der Bult","startDate":"2022-05-18","conditions":"Type 1 Diabetes, Diabetic Ketoacidosis","enrollment":2},{"nctId":"NCT06304857","phase":"PHASE3","title":"CardioPROTECTion with Dapagliflozin in Breast Cancer Patients Treated with AnthrAcycline - PROTECTAA TRIAL","status":"RECRUITING","sponsor":"4th Military Clinical Hospital with Polyclinic, Poland","startDate":"2024-04-15","conditions":"Breast Cancer, Heart Failure","enrollment":188},{"nctId":"NCT04170543","phase":"PHASE2","title":"A Phase 2b Diabetic Kidney Disease Study","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2019-11-18","conditions":"Diabetic Kidney Disease","enrollment":609},{"nctId":"NCT03199053","phase":"PHASE3","title":"Study to Evaluate Safety and Efficacy of Dapagliflozin and Saxagliptin in Patients With Type 2 Diabetes Mellitus (T2DM) Aged 10 to Below 18 Years Old","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2017-10-11","conditions":"Diabetes Mellitus, Type 2","enrollment":256},{"nctId":"NCT03190694","phase":"PHASE2","title":"Effects of Dapagliflozin in Non-diabetic Patients With Proteinuria","status":"COMPLETED","sponsor":"Hiddo Lambers Heerspink","startDate":"2017-11-12","conditions":"Chronic Kidney Diseases, Proteinuria","enrollment":53},{"nctId":"NCT04249778","phase":"PHASE4","title":"Dapagliflozin at Discharge on Hospital Heart Failure Readmission","status":"COMPLETED","sponsor":"Emory University","startDate":"2020-07-29","conditions":"Heart Failure, Diabetes","enrollment":105},{"nctId":"NCT05268926","phase":"PHASE2","title":"TreatIng Microalbuminuria Over 24 Weeks in Subjects With or Without Type 2 Diabetes or HYpertension","status":"TERMINATED","sponsor":"University Medical Center Groningen","startDate":"2022-02-03","conditions":"Albuminuria","enrollment":9},{"nctId":"NCT03782259","phase":"PHASE4","title":"Effects of SGLT-2 Inhibition on Myocardial Fibrosis and Inflammation as Assessed by Cardiac MRI in Patients With DM2","status":"COMPLETED","sponsor":"University of Washington","startDate":"2019-02-26","conditions":"Type 2 Diabetes Mellitus, Myocardial Fibrosis, Myocardial Inflammation","enrollment":62},{"nctId":"NCT06009874","phase":"NA","title":"Clinical Investigation of the Cardioprotective Effect of Early Administration of SGLT2 in Patients Presented With AMI","status":"RECRUITING","sponsor":"Mohammad Hussien Tantawy Soliman","startDate":"2023-10","conditions":"Myocardial Infarction","enrollment":80},{"nctId":"NCT03619213","phase":"PHASE3","title":"Dapagliflozin Evaluation to Improve the LIVEs of Patients With PReserved Ejection Fraction Heart Failure.","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2018-08-27","conditions":"Heart Failure With Preserved Ejection Fraction","enrollment":6263},{"nctId":"NCT03660683","phase":"PHASE4","title":"Effect of Saxagliptin and Dapagliflozin on Endothelial Progenitor Cell in Patients With Type 2 Diabetes Mellitus","status":"TERMINATED","sponsor":"Sabyasachi Sen","startDate":"2018-10-22","conditions":"Diabetes Mellitus, Type 2, Cardiovascular Diseases","enrollment":15},{"nctId":"NCT04080518","phase":"PHASE4","title":"Hepato-renal Regulation of Water Conservation in Heart Failure Patients With SGLT-2 Inhibitor Treatment","status":"COMPLETED","sponsor":"National Heart Centre Singapore","startDate":"2019-11-11","conditions":"Diabetes Mellitus, Heart Failure","enrollment":40},{"nctId":"NCT05710367","phase":"PHASE2","title":"Effects Of Sodium Glucose Cotranspoter 2 Inhibitors On Heart And Kidneys In Fabry Disease Patients","status":"UNKNOWN","sponsor":"Albina Nowak, MD","startDate":"2023-08","conditions":"Fabry Disease","enrollment":46},{"nctId":"NCT03030235","phase":"PHASE4","title":"Dapagliflozin in PRESERVED Ejection Fraction Heart Failure","status":"COMPLETED","sponsor":"Saint Luke's Health System","startDate":"2017-03-01","conditions":"Chronic Heart Failure With Preserved Systolic Function","enrollment":324},{"nctId":"NCT04350593","phase":"PHASE3","title":"Dapagliflozin in Respiratory Failure in Patients With COVID-19","status":"COMPLETED","sponsor":"Saint Luke's Health System","startDate":"2020-04-22","conditions":"COVID-19","enrollment":1250},{"nctId":"NCT03608358","phase":"PHASE3","title":"Safety and Efficacy of Dapagliflozin in Asian T2DM Subjects With Inadequate Glycemic Control on Metformin/Saxagliptin","status":"TERMINATED","sponsor":"AstraZeneca","startDate":"2019-02-27","conditions":"Type 2 Diabetes Mellitus","enrollment":41},{"nctId":"NCT02653482","phase":"PHASE4","title":"Dapagliflozin Effect on Symptoms and Biomarkers in Patients With Heart Failure","status":"COMPLETED","sponsor":"Saint Luke's Health System","startDate":"2016-03-03","conditions":"Chronic Heart Failure With Reduced Systolic Function","enrollment":263},{"nctId":"NCT03007329","phase":"PHASE4","title":"Effects of Combined Dapagliflozin and Exenatide Versus Dapagliflozin and Placebo on Ectopic Lipids in Patients With Uncontrolled Type 2 Diabetes Mellitus.","status":"COMPLETED","sponsor":"Medical University of Vienna","startDate":"2017-03-08","conditions":"Steatosis, Liver, Type2 Diabetes","enrollment":34},{"nctId":"NCT02725593","phase":"PHASE3","title":"Study to Evaluate Safety and Efficacy of Dapagliflozin in Patients With Type 2 Diabetes Mellitus Aged 10-24 Years","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2016-06-22","conditions":"Type 2 Diabetes","enrollment":72},{"nctId":"NCT03423355","phase":"PHASE4","title":"Dapagliflozin Effect on Erythropoiesis and Physical Fitness","status":"WITHDRAWN","sponsor":"University Hospital Tuebingen","startDate":"2021-09","conditions":"Type 2 Diabetes Mellitus (T2DM)","enrollment":""},{"nctId":"NCT04170998","phase":"PHASE3","title":"Efficacy and Safety of Evogliptin When Added to Ongoing Metformin and Dapagliflozin Combination Therapy in Patients With Type 2 Diabetes Who Have Inadequate Glycemic Control","status":"COMPLETED","sponsor":"Dong-A ST Co., Ltd.","startDate":"2020-01-02","conditions":"Type2 Diabetes","enrollment":283},{"nctId":"NCT03721874","phase":"PHASE4","title":"Effects of 2 Weeks Treatment With Dapagliflozin in Subjects With an Impaired Glucose Homeostasis on Nocturnal Substrate Oxidation","status":"COMPLETED","sponsor":"Maastricht University","startDate":"2019-04-30","conditions":"Prediabetic State, Substrate Oxidation","enrollment":16},{"nctId":"NCT03036150","phase":"PHASE3","title":"A Study to Evaluate the Effect of Dapagliflozin on Renal Outcomes and Cardiovascular Mortality in Patients With Chronic Kidney Disease","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2017-02-02","conditions":"Chronic Kidney Disease","enrollment":4304},{"nctId":"NCT04219124","phase":"PHASE4","title":"The Effect of a SGLT2 Inhibitor on Glucose Flux, Lipolysis and Exercise in Type 2 Diabetes","status":"COMPLETED","sponsor":"University of Leicester","startDate":"2018-09-20","conditions":"Type 2 Diabetes","enrollment":9},{"nctId":"NCT03338855","phase":"PHASE4","title":"Effects of 5 Weeks Treatment With Dapagliflozin in Type 2 Diabetes Patients on How the Hormone Insulin Acts on Sugar Uptake in Muscles.","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2018-03-05","conditions":"Diabetes Mellitus, Type 2, Skeletal Muscle Insulin Sensitivity","enrollment":26},{"nctId":"NCT03036124","phase":"PHASE3","title":"Study to Evaluate the Effect of Dapagliflozin on the Incidence of Worsening Heart Failure or Cardiovascular Death in Patients With Chronic Heart Failure","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2017-02-08","conditions":"Chronic Heart Failure With Reduced Ejection Fraction (HFrEF)","enrollment":4744},{"nctId":"NCT02608905","phase":"PHASE4","title":"Effect of Dapagliflozin on Inflammation and Endothelial Function","status":"TERMINATED","sponsor":"Baylor College of Medicine","startDate":"2015-11","conditions":"Type 2 Diabetes Mellitus","enrollment":17},{"nctId":"NCT03556033","phase":"PHASE2","title":"Effect of Dapagliflozin on IAH in T1DM","status":"COMPLETED","sponsor":"Radboud University Medical Center","startDate":"2018-11-23","conditions":"Diabetes Mellitus, Type 1, Hypoglycemia, Hypoglycemia Unawareness","enrollment":15},{"nctId":"NCT03180489","phase":"PHASE2","title":"Does Dapagliflozin Provide Additional Health Benefits To Dietary Counseling For Weight Loss?","status":"COMPLETED","sponsor":"Christopher Bell","startDate":"2017-05-03","conditions":"Weight Loss","enrollment":62},{"nctId":"NCT03444584","phase":"PHASE2","title":"Study of MEDI0382 in Combination With Dapagliflozin and Metformin in Overweight/Obese Participants With Type 2 Diabetes","status":"COMPLETED","sponsor":"MedImmune LLC","startDate":"2018-05-08","conditions":"Type 2 Diabetes Mellitus","enrollment":49},{"nctId":"NCT03316131","phase":"PHASE2","title":"A Study to Assess the Effect of Intensive Uric Acid (UA) Lowering Therapy With RDEA3170, Febuxostat, Dapagliflozin on Urinary Excretion of UA","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2017-10-25","conditions":"Asymptomatic Hyperuricemia","enrollment":36},{"nctId":"NCT02547935","phase":"PHASE2, PHASE3","title":"A Study to Evaluate the Effect of Dapagliflozin With and Without Saxagliptin on Albuminuria, and to Investigate the Effect of Dapagliflozin and Saxagliptin on HbA1c in Patients With Type 2 Diabetes and CKD","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2015-09-21","conditions":"Type 2 Diabetes Mellitus, CKD and Albuminuria","enrollment":459},{"nctId":"NCT02956811","phase":"PHASE4","title":"Does Dapagliflozin Regress Left Ventricular Hypertrophy In Patients With Type 2 Diabetes?","status":"COMPLETED","sponsor":"University of Dundee","startDate":"2017-02-14","conditions":"Type 2 Diabetes, Left Ventricular Hypertrophy","enrollment":66},{"nctId":"NCT02520518","phase":"PHASE2","title":"Does Dapagliflozin Promote Favorable Health Benefits That Are Independent Of Weight Loss?","status":"TERMINATED","sponsor":"Christopher Bell","startDate":"2015-08","conditions":"Weight Loss","enrollment":9},{"nctId":"NCT02229396","phase":"PHASE3","title":"Phase 3 28-Week Study With 24-Week and 52-week Extension Phases to Evaluate Efficacy and Safety of Exenatide Once Weekly and Dapagliflozin Versus Exenatide and Dapagliflozin Matching Placebo","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2014-09-04","conditions":"Diabetes Mellitus","enrollment":695},{"nctId":"NCT02532855","phase":"PHASE3","title":"A Study to Assess the Addition of Sitagliptin to Metformin Compared With the Addition of Dapagliflozin to Metformin in Participants With Type 2 Diabetes Mellitus (T2DM) and Mild Renal Impairment Who Have Inadequate Glycemic Control on Metformin With or Without a Sulfonylurea (MK-0431-838)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2015-10-20","conditions":"Type 2 Diabetes Mellitus","enrollment":614},{"nctId":"NCT02413398","phase":"PHASE3","title":"A Study to Evaluate the Effect of Dapagliflozin on Blood Glucose Level and Renal Safety in Patients With Type 2 Diabetes","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2015-06-15","conditions":"Type 2 Diabetes Mellitus","enrollment":321},{"nctId":"NCT02397421","phase":"PHASE4","title":"Safety and Effectiveness of SGLT-2 Inhibitors in Patients With Heart Failure and Diabetes","status":"COMPLETED","sponsor":"University of Dundee","startDate":"2015-03","conditions":"Heart Failure, Diabetes","enrollment":56},{"nctId":"NCT02284893","phase":"PHASE3","title":"Study to Evaluate the Efficacy and Safety of Saxagliptin Co-administered With Dapagliflozin in Combination With Metformin Compared to Sitagliptin in Combination With Metformin in Adult Patients With Type 2 Diabetes Who Have Inadequate Glycemic Control on Metformin Therapy Alone","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2014-09-09","conditions":"Type 2 Diabetes","enrollment":461},{"nctId":"NCT02426541","phase":"PHASE4","title":"Effects of Dapagliflozin 10 mg on Insulin Resistance in Patients With Type 2 Diabetes Mellitus","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2015-03-23","conditions":"Type 2 Diabetes Mellitus","enrollment":55},{"nctId":"NCT01606007","phase":"PHASE3","title":"Safety and Efficacy of Combination Saxagliptin & Dapagliflozin Added to Metformin to Treat Subjects With Type 2 Diabetes","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2012-07","conditions":"Type 2 Diabetes","enrollment":1282},{"nctId":"NCT00683878","phase":"PHASE3","title":"Add-on to Thiazolidinedione (TZD) Failures","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2008-07","conditions":"Type 2 Diabetes","enrollment":972},{"nctId":"NCT01498185","phase":"PHASE2","title":"BMS - Safety, Pharmacokinetics (PK) and Pharmacodynamics (PD) of Dapagliflozin in Type 1 Diabetes","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2012-02","conditions":"Type 1 Diabetes Mellitus","enrollment":171},{"nctId":"NCT01137474","phase":"PHASE3","title":"A Study of BMS-512148 (Dapagliflozin) in Patients With Type 2 Diabetes and Inadequately Controlled Hypertension on an Angiotensin-Converting Enzyme Inhibitor or Angiotensin Receptor Blocker","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2010-07","conditions":"Type 2 Diabetes","enrollment":2996},{"nctId":"NCT01195662","phase":"PHASE3","title":"A Study of BMS-512148 (Dapagliflozin) in Patients With Type 2 Diabetes With Inadequately Controlled Hypertension on an ACEI or ARB and an Additional Antihypertensive Medication","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2010-10","conditions":"Type 2 Diabetes","enrollment":2245},{"nctId":"NCT00859898","phase":"PHASE3","title":"Study of Dapagliflozin in Combination With Metformin XR to Initiate the Treatment of Type 2 Diabetes","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2009-04","conditions":"Type 2 Diabetes Mellitus","enrollment":1093},{"nctId":"NCT01646320","phase":"PHASE3","title":"Safety and Efficacy of Dapagliflozin in Triple Therapy to Treat Subjects With Type 2 Diabetes","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2012-09","conditions":"Type 2 Diabetes","enrollment":320},{"nctId":"NCT01619059","phase":"PHASE3","title":"Safety and Efficacy of Saxagliptin in Triple Therapy to Treat Subjects With Type 2 Diabetes","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2012-06","conditions":"Type 2 Diabetes","enrollment":315},{"nctId":"NCT00528879","phase":"PHASE3","title":"A Phase III Study of BMS-512148 (Dapagliflozin) in Patients With Type 2 Diabetes Who Are Not Well Controlled on Metformin Alone","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2007-09","conditions":"Type 2 Diabetes","enrollment":915},{"nctId":"NCT01294423","phase":"PHASE3","title":"Evaluate Efficacy and Safety in Japanese Subjects With Type 2 Diabetes Mellitus","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2011-02","conditions":"Type 2 Diabetes, High Blood Sugar","enrollment":261},{"nctId":"NCT00984867","phase":"PHASE3","title":"Dapagliflozin DPPIV Inhibitor add-on Study","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2009-10","conditions":"Type 2 Diabetes","enrollment":833},{"nctId":"NCT01392677","phase":"PHASE3","title":"Evaluation of Safety and Efficacy of Dapagliflozin in Subjects With Type 2 Diabetes Who Have Inadequate Glycaemic Control on Background Combination of Metformin and Sulfonylurea","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2011-10","conditions":"Type 2 Diabetes Mellitus, High HbA1c Level, Inadequate Glycaemic Control","enrollment":311},{"nctId":"NCT01042977","phase":"PHASE3","title":"Efficacy and Safety in Patients With Type 2 Diabetes Mellitus and Cardiovascular Disease","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2010-03","conditions":"Type 2 Diabetes Mellitus, Cardiovascular Disease, Inadequate Glycaemic Control","enrollment":964},{"nctId":"NCT01031680","phase":"PHASE3","title":"Efficacy and Safety in Patients With Type 2 Diabetes Mellitus, Cardiovascular Disease and Hypertension","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2010-02","conditions":"Type 2 Diabetes Mellitus, Cardiovascular Disease, Hypertension","enrollment":922},{"nctId":"NCT00855166","phase":"PHASE3","title":"Evaluation of the Effect of Dapagliflozin in Combination With Metformin on Body Weight in Subjects With Type 2 Diabetes","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2009-02","conditions":"Type 2 Diabetes Mellitus","enrollment":182}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":44,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"Placebo matching with Dapagliflozin","genericName":"Placebo matching with Dapagliflozin","companyName":"AstraZeneca","companyId":"astrazeneca","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Dapagliflozin inhibits sodium-glucose cotransporter 2 (SGLT2) in the kidney to increase urinary glucose excretion and lower blood glucose levels. Used for Type 2 diabetes mellitus, Heart failure with reduced ejection fraction, Chronic kidney disease.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":1,"withResults":1},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}